Teng Xue

Teng Xue

Auto-generated profile, based on publicly available information

Teng Xue

Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University 2 , Beijing

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2021 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
RZRui Zhang
Rui Zhang
TXTeng Xue
Teng Xue
ASAnwen Shao
Anwen Shao
YLYue Lang
Yue Lang
CQChao Qin
Chao Qin
JTJun Tang
Jun Tang

20 August 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
KTKaiyang Tang
Kaiyang Tang
LWLijian Wu
Lijian Wu
YHYuanzhi Hu
Yuanzhi Hu
TXTeng Xue
Teng Xue
YJYiteng Jin
Yiteng Jin
DPDeng Pan
Deng Pan
Effective immunotherapy relies on the presentation of tumor-derived neoantigens on the major histocompatibility complex class I (MHC-I) to activate CD8+ T cells. Deficiencies in this process are a key mechanism of immune evasion and resistance to checkpoint blockade. In this study, using an in vivo CRISPR-Cas9 screen, we unexpectedly found that inactivation of calreticulin (CALR), and other selected components of the peptide-loading complex (PLC), induced robust CD8+ T cell–mediated immune responses. We show that this effect is dependent on the expression of classical MHC-I on tumor cells. Mechanistically, loss of CALR reshaped the MHC-I peptide repertoire, favoring the presentation of low-affinity peptides in murine and human cell lines. Genetic or pharmacological inhibition of PDIA3, another PLC component, similarly induced antitumor effects. These findings reveal a previously unrecognized role of CALR and the PLC in regulating antitumor immunity and suggest that targeting this pathway could be a promising strategy to overcome immune resistance and improve the efficacy of cancer immunotherapies.